Statens Serum Institut: Clinical Trials

12 trials sponsored by Statens Serum Institut, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

12 completed. 12 Phase 3, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	12	Completed 12
Phase 2	3	Completed 3

Follow Statens Serum Institut: new trials by email

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months IPV-Al SSI - Poliomyelitis	Phase 3	Completed	Statens Serum Institut	666	2018-05-15	2018-11-14
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months IPV-Al SSI, IPV SSI - Poliomyelitis	Phase 3	Completed	Statens Serum Institut	1002	2017-02-06	2018-11-14
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age IPV-Al SSI, IPV SSI - Poliomyelitis	Phase 3	Completed	Statens Serum Institut	800	2017-01-19	2018-11-14
Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses C-Tb, Tuberculin PPD RT 23 SSI, C-Tb / Tuberculin PPD RT 23 SSI - Tuberculosis	Phase 2 / Phase 3	Completed	Statens Serum Institut	456	2013-10-01	2015-04-17
A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI C-Tb, 2 T.U. Tuberculin PPD RT 23 SSI - Tuberculosis	Phase 3	Completed	Statens Serum Institut	1190	2012-09-01	2016-04-14
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI C-Tb, 2 T.U. Tuberculin PPD RT 23 SSI - Tuberculosis	Phase 3	Completed	Statens Serum Institut	979	2012-07-01	2015-04-17
Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults TdaP vaccine SSI, Td vaccine SSI - Healthy	Phase 3	Completed	Statens Serum Institut	802	2010-01-01	2013-01-21
The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes nexium, Yoghurt, placebo+placebo - Type 2 Diabetes	Phase 3	Completed	Lise Tarnow	41	2008-06-01	2012-09-03
Therapeutic Zinc in Childhood Pneumonia Zinc (zinc sulphate), Placebo - Pneumonia	Phase 2 / Phase 3	Completed	Centre For International Health	641	2006-01-01	2009-10-06
CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia Zinc - Pneumonia	Phase 2 / Phase 3	Completed	Centre For International Health	2628	2004-01-01	2022-03-16
Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine DTaP-IPV vero vaccine, DTaP-IPV mkc vaccine - Active Immunization	Phase 3	Completed	Statens Serum Institut	817	2003-09-01	2013-01-21
Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria BCG - Malaria	Phase 3	Completed	London School of Hygiene and Tropical Medicine	1200	2003-01-01	2016-09-02

Conditions studied

Interventions

Countries

Top investigators

Results publications